Vir Biotechnology VIR
$8.39 −$0.48 (-5.41%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $8.30 -1.05%
Open$8.77
Prev close$8.87
Day range$8.34 – $8.92
Volume3.09M
Market cap$1.56B
P/E (TTM)–
Dividend yield–
VIR Stock News
Headlines matching Vir Biotechnology or the VIR ticker, most recent first.
- Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $17 Negative
- Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18
- H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20
- BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $15 Negative
- A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $15 to $30
- A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $18 to $30
- Insiders Of Vir Biotechnology Make A Tidy Sum Selling At US$8.85
- Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Sutro Biopharma (STRO) and Ardent Health Partners, Inc. (ARDT)
- Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Raises Target Price to $27 Positive
- Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $30
- A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $16 to $30
- Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $23 Negative
- Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Hatfield Jeffrey S.
- Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating
- BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $16
No comments yet — be the first to weigh in on VIR.
Sign in to join the discussion.